GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd (SHSE:688336) » Definitions » 3-Year EPS without NRI Growth Rate

Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) 3-Year EPS without NRI Growth Rate : 0.00% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sunshine Guojian Pharmaceutical (Shanghai) Co 3-Year EPS without NRI Growth Rate?

Sunshine Guojian Pharmaceutical (Shanghai) Co's EPS without NRI for the three months ended in Sep. 2024 was ¥0.16.

During the past 12 months, Sunshine Guojian Pharmaceutical (Shanghai) Co's average EPS without NRI Growth Rate was 51.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Sunshine Guojian Pharmaceutical (Shanghai) Co was 28.30% per year. The lowest was -49.70% per year. And the median was 3.35% per year.


Competitive Comparison of Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year EPS without NRI Growth Rate falls into.



Sunshine Guojian Pharmaceutical (Shanghai) Co 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Sunshine Guojian Pharmaceutical (Shanghai) Co  (SHSE:688336) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Sunshine Guojian Pharmaceutical (Shanghai) Co 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sunshine Guojian Pharmaceutical (Shanghai) Co's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Traded in Other Exchanges
N/A
Address
No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
Executives
Weng Zhi Bing Core technical personnel
Huang Hao Min Core technical personnel

Sunshine Guojian Pharmaceutical (Shanghai) Co Headlines

No Headlines